Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist
AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat